Biochemical markers and cells count in peripheral blood in patients with tuberculosis according to CYP2C9 genotype
Abstract
The aim of present work was detection of peculiarities of pulmonary tuberculosis course depending on cytochrome-450 2C9 (CYP2C9) polymorphism according on cellular content of cells count and biochemical markers of the blood. it was done analysis of 83 medical card of primary pulmonary tuberculosis at the beginning and at the end of in-patient treatment in Odessa district dispensary in 2012 y. At the beginning and at the end of in-patient treatment the patients with genotype *2/*3, *3/*3 have had the highest level of erythrocytes and hemoglobin, and the lowest level of erythrocytes sedimentation rate that witnessed the slight intoxication. Also in this group of patients it was found the highest level of alanine aminotransferase and gamma glutathione transferase that have proved higher risk of toxicity of antituberculosis therapy in the carriers of *2/*3, *3/*3 genotype relatively to carriers of *1/*1, *1/*2, *1/*3 genotypes.
References
1. Falzon D., Jaramillo E., Schünemann H.J., Arentz M., Bauer M., Bayona J. et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update // Eur. respir. j. - 2011. -№ 38 (3). - Р. 516-528.
2. Фещенко Ю.И., Мельник В.М., Матусевич В.Г., Линник Н.И. и др. Оценка контроля туберкулеза в Украине за период 2006-2010 годы // Украинский пульмонологический журнал. - 2011. - № 4. -С. 5-10.
3. Фещенко Ю.И., Черенько C.А., Красильникова Н.П., Мальцев В.И. и др. Регистрация побочных реакций противотуберкулезных препаратов при лечении больных туберкулезом // Украинский пульмонологический журнал. - 2008. - № 4. - С. 8-13.
4. Ramachandran Geetha. Swaminathan soumya role of pharmacogenomics in the treatment of tuberculosis: a review // Pharmacogenomics and personalized medicine. - 2012. - № 5. -Р. 89-98.
5. Castillejos-López Mde J., García-Sancho M.C., Quiñones-Falconi F., Pérez-Padilla J.R. Cytochrome P450 and NAT2 polymorphisms and drug metabolism in DOTS // Rev. invest. clin. -2008. - № 60 (1). - Р. 47-57.
6. Zhou S.F., Zhou Z.W., Yang L.P., Cai J.P. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development // Cur. med. chem. - 2009. - № 16 (27). - Р. 3480-3675.
7. Антоненко П.Б., Кресюн В.И. Полиморфизм генотипа цитохрома-450 2С9 в Одесском регионе // Актуальные проблемы современной медицини. - 2011. - № 11 (4). - С. 51-55.
8. Tatarũnas V., Lesauskaité V., Veikutiené A., Jakuška P., Benetis R. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement // Medicina (Kaunas). - 2011. - № 47 (1). - Р. 25-30.
9. Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M., Brockmöller J., Frötschl R., Köpke K. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population // Eur. j. clin. pharmacol. - 2003. - № 59 (4). -Р. 303-312.
10. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.Y., Kaminsky L.S., Shenfield G.M. et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism // Pharmacogenetics. -1996. - № 6 (4). - Р. 341-349.
11. Стальная И.Д. Современные методы в биохимии. - М.: Медицина, 1977. - С. 63.
12. Бялик И.Б., Цыганкова Л.М., Давиденко В.В., Случ И.В. Результаты применения ПАСК в комплексной химиотерапии больных деструктивным, ранее неэффективно леченным, химиорезистентным туберкулезом легких // Украинский пульмонологический журнал. - 2006. - № 1. - С. 56-60.
Review
For citations:
Antonenko P.B. Biochemical markers and cells count in peripheral blood in patients with tuberculosis according to CYP2C9 genotype. Kuban Scientific Medical Bulletin. 2014;(2):12-16. (In Russ.)
Views:
247
Email this article 